BiotechTube

ceftobiprole medocaril + Vancomycin plus Ceftazidime

Phase 3Completed
0 watching 0 views this week📈 Rising
72
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Skin Diseases, Infectious

Conditions

Skin Diseases, Infectious, Skin Diseases, Bacterial, Staphylococcal Skin Infections

Trial Timeline

Sep 1, 2005 → Oct 1, 2006

NCT ID
NCT00210899

About ceftobiprole medocaril + Vancomycin plus Ceftazidime

ceftobiprole medocaril + Vancomycin plus Ceftazidime is a phase 3 stage product being developed by Basilea Pharmaceutica for Skin Diseases, Infectious. The current trial status is completed. This product is registered under clinical trial identifier NCT00210899. Target conditions include Skin Diseases, Infectious, Skin Diseases, Bacterial, Staphylococcal Skin Infections.

Hype Score Breakdown

Clinical
27
Activity
18
Company
5
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT00210899Phase 3Completed

Competing Products

20 competing products in Skin Diseases, Infectious

See all competitors
ProductCompanyStageHype Score
[203Pb]VMT01 + [212Pb]VMT01 + NivolumabPerspective TherapeuticsPhase 1/2
33
[203Pb]VMT01 + [68Ga]VMT02Perspective TherapeuticsPhase 1
25
Mupirocin Calcium Cream, 2% + Bactroban® Cream + Cream vehicle of test productSun PharmaceuticalPhase 1
33
LY3041658 + PlaceboEli LillyPhase 1
33
DSP-9632P 27.5 mg + DSP-9632P 82.5 mg + Placebo + DSP-9632P 55.0 mg + Levodopa formulationSumitomo PharmaPhase 1
33
levofloxacinJohnson & JohnsonPhase 2/3
65
Moisturizer A, F#9155-005Johnson & JohnsonPre-clinical
23
levofloxacinJohnson & JohnsonPhase 3
77
CeftobiproleJohnson & JohnsonPhase 1
33
Natural Killer Cell Therapy + Universal Donor Expanded TGF-beta-imprinted NK CellsJohnson & JohnsonPhase 1
33
LevofloxacinJohnson & JohnsonPhase 3
77
CeftobiproleJohnson & JohnsonPhase 1
33
Levodopa-carbidopa intestinal gelAbbViePhase 3
77
IressaAstraZenecaPhase 2
52
Daptomycin + VancomycinAstraZenecaPhase 3
77
SarizotanMerckPre-clinical
23
Pembrolizumab + EDP1503MerckPhase 2
52
testosterone gel + Comparator: placeboMerckPhase 1
33
LNS8801 + Pembrolizumab + Chemotherapy (dacarbazine or temozolomide) + Immunotherapy (Pembrolizumab) + Immunotherapy (nivolumab and relatlimab) + Immunotherapy (ipilimumab and nivolumab)MerckPhase 2/3
65
Vancomycin + Daptomycin + Semi-Synthetic PenicillinMerckApproved
85

Other Products from Basilea Pharmaceutica

alitretinoinPhase 3
72
ceftobiprole medocaril + vancomycin+aztreonamPhase 3
72
alitretinoinPhase 3
72
Fosmanogepix + Fosmanogepix + Caspofungin + Fluconazole + Placebo + Placebo + Placebo + PlaceboPhase 3
72
ceftobiprole plus placebo + linezolid plus ceftazidimePhase 3
72